| Project/Area Number |
22K12384
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 63020:Radiation influence-related
|
|---|
| Research Institution | National Institutes for Quantum Science and Technology |
|---|
Principal Investigator |
楊 国勝 国立研究開発法人量子科学技術研究開発機構, 放射線医学研究所 計測・線量評価部, 主任研究員 (10801227)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
金 ウンジュ 国立研究開発法人量子科学技術研究開発機構, 放射線医学研究所 計測・線量評価部, 主幹研究員 (10370876)
鄭 建 国立研究開発法人量子科学技術研究開発機構, 放射線医学研究所 計測・線量評価部, 上席研究員 (30370878)
|
|---|
| Project Period (FY) |
2022-04-01 – 2025-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2024: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2023: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2022: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | Atctinides / Bioassay / Radiation emergency / PROCORAD intercomparison / ICP-MS/MS / Alpha spectrometry / Actinides / Dose assessment / Cell gas / アクチニド / バイオアッセイ / 被ばく医療 / 質量分析法 |
|---|
| Outline of Research at the Start |
東電福島第一原発廃炉作業及び日本原燃再処理施設の稼働の本格化に伴い、放射線作業員のアクチニド内部被ばく事故リスクの増加が懸念されており、効果的・効率的な内部被ばく線量評価手法の開発は急務である。そこで、本研究では、プルトニウム(Pu)を含むアクチニド核種による内部被ばく事故に備え、血液、尿及び便を対象に、迅速かつ高感度の質量分析アクチニド・バイオアッセイ手法の開発を目的とする。本研究での成果は、既存の放射能測定法を最適化することに加え、開発した質量分析法との併用により、被ばく医療対応の実効性向上と体内除染剤の機序解明などの新たな研究分野の開拓に寄与できる。
|
| Outline of Annual Research Achievements |
The developed urinary bioassay methods in last year were applied to measured U, Pu, and Am isotopes by ICP-MS/MS in the urinary samples collected during the Oarai Pu/Am exposure accident. The data of ICP-MS/MS were comparable with that of alpha spectrometry. In addition, the developed urinary and fecal bioassay methods were also applied to participate in the annual intercomparison organized by PROCORAD, France. Based on the performance criteria including Z-score, bias, and En value, our lab qualified as TOP LABO for these comparisons: Actinides in urine with DTPA (2023), Actinides in urine (2023), and Uranium in fecal ashes (2023). These indicated the developed urinary and fecal bioassay methods are able to measure actinides rapidly in urinary and fecal samples.
|
| Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
This year, we focused on the application of the developed urinary and fecal bioassay methods to measure actinides in contaminated urinary samples and participate in interlaboratory comparison for method validation. The development of bioassay method in blood to measure actinides was somewhat delayed.
|
| Strategy for Future Research Activity |
The development of fecal bioassay method to measure actinides by ICP-MS/MS are expected to be published as papers. The development of bioassay method for the measurement of actinides in blood sample will be performed in this year. The remaining urinary samples collected during the Oarai Pu/Am exposure accident will be measured by the developed methods with ICP-MS/MS, to compare with that of alpha spectrometry. In addition, the developed methods could also provide additional information, such as the 240Pu/239Pu atom ratio, uranium isotopes.
|
